Trials / Completed
CompletedNCT06045221
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Once Daily Oral LY3502970 Compared With Oral Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (ACHIEVE-3)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,698 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to assess efficacy and safety of orforglipron compared with oral semaglutide in participants with Type 2 diabetes and inadequate glycemic control with metformin.The study will last around 61 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Orforglipron | Administered orally |
| DRUG | Semaglutide | Administered orally |
Timeline
- Start date
- 2023-09-22
- Primary completion
- 2025-08-22
- Completion
- 2025-08-22
- First posted
- 2023-09-21
- Last updated
- 2025-09-22
Locations
131 sites across 6 countries: United States, Argentina, China, Japan, Mexico, Puerto Rico
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06045221. Inclusion in this directory is not an endorsement.